Esp
Archive page for Esp
Abevmy
Abevmy®
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
Fallopian tube cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer
DATE:
23/02/2024
STATUS:
Authorized
Uzpruvo
Uzpruvo®
ACTIVE PRINCIPLE:
Believable
INDICATION:
plaque psoriasis
Psoriasic arthritis
Crohn's disease
Ulcerative colitis
DATE:
11/01/2024
STATUS:
Authorized
Tyruko®
Tyruko®
ACTIVE PRINCIPLE:
natalizumab
INDICATION:
Multiple sclerosis
DATE:
29/09/2023
STATUS:
Authorized
Tyenne®
Tyenne®
ACTIVE PRINCIPLE:
Tocilizumab
INDICATION:
Rheumatoid Arthritis
Cytokine release syndrome
Juvenile rheumatoid arthritis
COVID-19 virus infection
Giant cell arteritis
DATE:
21/09/2023
STATUS:
Authorized
Epysqli®
Epysqli®
ACTIVE PRINCIPLE:
eculizumab
INDICATION:
paroxysmal hemoglobinuria
DATE:
20/06/2023
STATUS:
Authorized
MORE INFORMATION
Bekemv®
Bekemv®
ACTIVE PRINCIPLE:
eculizumab
INDICATION:
paroxysmal hemoglobinuria
DATE:
27/04/2023
STATUS:
Authorized
MORE INFORMATION
Byooviz®
Byooviz®
ACTIVE PRINCIPLE:
ranibizumab
INDICATION:
wet macular degeneration
Macular edema
Diabetic retinopathy
diabetic complications
DATE:
27/04/2023
STATUS:
Authorized
MORE INFORMATION
Ximluci®
Ximluci®
ACTIVE PRINCIPLE:
ranibizumab
INDICATION:
wet macular degeneration
Macular edema
Diabetic retinopathy
diabetic complications
DATE:
22/11/2022
STATUS:
Authorized
MORE INFORMATION
Vegzelma®
Vegzelma®
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
Fallopian tube cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer
DATE:
05/10/2022
STATUS:
Authorized
Ranivisio®
Ranivisio®
ACTIVE PRINCIPLE:
ranibizumab
INDICATION:
wet macular degeneration
Macular edema
Diabetic retinopathy
diabetic complications
DATE:
29/09/2022
STATUS:
Authorized
MORE INFORMATION
Sondelbay®
Sondelbay®
ACTIVE PRINCIPLE:
teriparatide
INDICATION:
Osteoporosis
DATE:
06/06/2022
STATUS:
Authorized
Stimufend®
Stimufend®
ACTIVE PRINCIPLE:
Pegfilgrastim
INDICATION:
neutropenia
DATE:
17/05/2022
STATUS:
Authorized
Hukyndra®
Hukyndra®
ACTIVE PRINCIPLE:
Adalimumab
INDICATION:
Psoriasic arthritis
Juvenile rheumatoid arthritis
Rheumatoid Arthritis
Ulcerative colitis
Crohn's disease
Hidradenitis suppurativa
Psoriasis
Ankylosing spondylitis
Uveitis
DATE:
28/12/2021
STATUS:
Authorized
MORE INFORMATION
ALYMSYS®
ALYMSYS®
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer
DATE:
28/05/2021
STATUS:
Authorized
Oyavas®
Oyavas®
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
Fallopian tube cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer
DATE:
08/04/2021
STATUS:
Authorized
Yuflyma®
Yuflyma®
ACTIVE PRINCIPLE:
Adalimumab
INDICATION:
Rheumatoid Arthritis
Juvenile rheumatoid arthritis
Psoriasis
Psoriasic arthritis
Ankylosing spondylitis
Uveitis
Ulcerative colitis
Crohn's disease
Hidradenitis suppurativa
DATE:
31/03/2021
STATUS:
Authorized
MORE INFORMATION
Nyvepria®
Nyvepria®
ACTIVE PRINCIPLE:
Pegfilgrastim
INDICATION:
neutropenia
DATE:
08/01/2021
STATUS:
Authorized
Equidacent®
Equidacent®
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
Non-small cell lung carcinoma
Renal cell carcinoma
DATE:
29/12/2020
STATUS:
Authorized
Livogiva®
Livogiva®
ACTIVE PRINCIPLE:
teriparatide
INDICATION:
Osteoporosis
DATE:
20/10/2020
STATUS:
Authorized
Aybintio®
Aybintio®
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
colorectal cancer
Breast cancer
Ovarian cancer
Fallopian tube cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer
DATE:
07/09/2020
STATUS:
Authorized
MORE INFORMATION
Zercepac®
Zercepac®
ACTIVE PRINCIPLE:
trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
03/08/2020
STATUS:
Authorized
MORE INFORMATION
Ruxience®
Ruxience®
ACTIVE PRINCIPLE:
Rituximab
INDICATION:
B-cell chronic lymphocytic leukemia
Rheumatoid Arthritis
microscopic polyangiitis
Pemphigus
DATE:
26/04/2020
STATUS:
Authorized
Fulphila®
Fulphila®
ACTIVE PRINCIPLE:
pegfilgrastim
INDICATION:
neutropenia
DATE:
25/10/2019
STATUS:
Authorized
Zirabev®
Zirabev®
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colon or rectal carcinoma
Breast cancer
Non-small cell lung cancer
renal cell cancer
Cervical cancer
DATE:
30/09/2019
STATUS:
Authorized
Mvasi®
Mvasi®
ACTIVE PRINCIPLE:
Bevacizumab
INDICATION:
Colon or rectal carcinoma
Breast cancer
Non-small cell lung cancer
renal cell cancer
Ovarian, fallopian tube and peritoneal cancer
Cervical cancer
DATE:
27/09/2019
STATUS:
Authorized
Enoxaparin Ledraxen®
Enoxaparin Ledraxen®
ACTIVE PRINCIPLE:
Enoxaparin Sodium
INDICATION:
venous thrombosis
DATE:
08/08/2019
STATUS:
Authorized
Idacio®
Idacio®
ACTIVE PRINCIPLE:
adalimumab
INDICATION:
Rheumatoid Arthritis
Juvenile rheumatoid arthritis
Psoriasic arthritis
Ulcerative colitis
Crohn's disease
Psoriasis
Ankylosing spondylitis
Hidradenitis suppurativa
Uveitis
DATE:
08/07/2019
STATUS:
Authorized
ENOXAPARIN GINELADIUS®
ENOXAPARIN GINELADIUS®
ACTIVE PRINCIPLE:
Enoxaparin Sodium
INDICATION:
venous thrombosis
DATE:
23/05/2019
STATUS:
Authorized
Ogivri®
Ogivri®
ACTIVE PRINCIPLE:
trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
28/02/2019
STATUS:
Authorized
Semglee®
Semglee®
ACTIVE PRINCIPLE:
Insulin glargine
INDICATION:
Diabetes mellitus type 2
DATE:
25/02/2019
STATUS:
Authorized
Ziextenzo®
Ziextenzo®
ACTIVE PRINCIPLE:
Pegfilgrastim
INDICATION:
neutropenia
DATE:
08/02/2019
STATUS:
Authorized
Earthy®
Earthy®
ACTIVE PRINCIPLE:
teriparatide
INDICATION:
Osteoporosis
DATE:
31/01/2019
STATUS:
Authorized
PELMEG®
PELMEG®
ACTIVE PRINCIPLE:
Pegfilgrastim
INDICATION:
neutropenia
DATE:
12/12/2018
STATUS:
Authorized
Trazimera®
Trazimera®
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
breast and stomach cancer
DATE:
30/11/2018
STATUS:
Authorized
Hulio®
Hulio®
ACTIVE PRINCIPLE:
adalimumab
INDICATION:
Ankylosing spondylitis
uveitis
Rheumatoid Arthritis
Hidradenitis suppurativa
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
Psoriasis
DATE:
15/11/2018
STATUS:
Authorized
Pelgraz®
Pelgraz®
ACTIVE PRINCIPLE:
Pegfilgrastim
INDICATION:
neutropenia
DATE:
31/10/2018
STATUS:
Authorized
HEPAXANE®
HEPAXANE®
ACTIVE PRINCIPLE:
Enoxaparin Sodium
INDICATION:
venous thrombosis
DATE:
27/09/2018
STATUS:
Authorized
Hyrimoz®
Hyrimoz®
ACTIVE PRINCIPLE:
adalimumab
INDICATION:
Ankylosing spondylitis
uveitis
Rheumatoid Arthritis
Hidradenitis suppurativa
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
papulosquamous diseases
Juvenile rheumatoid arthritis
DATE:
16/08/2018
STATUS:
Authorized
Movymia®
Movymia®
ACTIVE PRINCIPLE:
teriparatide
INDICATION:
Osteoporosis
DATE:
01/08/2018
STATUS:
Authorized
Zessly®
Zessly®
ACTIVE PRINCIPLE:
Infliximab
INDICATION:
Ankylosing spondylitis
Rheumatoid arthritis
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
Psoriasis
DATE:
16/07/2018
STATUS:
Authorized
Kanjinti®
Kanjinti®
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
28/05/2018
STATUS:
Authorized
Imraldi®
Imraldi®
ACTIVE PRINCIPLE:
adalimumab
INDICATION:
Ankylosing spondylitis
Arthritis
Uveitis
Rheumatoid Arthritis
Hidradenitis suppurativa
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
Psoriasis
DATE:
25/05/2018
STATUS:
Authorized
Amgevita®
Amgevita®
ACTIVE PRINCIPLE:
Adalimumab
INDICATION:
Rheumatoid Arthritis
Juvenile idiopathic arthritis
axial spondylitis
Psoriasic arthritis
Psoriasis
Pediatric plaque psoriasis
Hidradenitis suppurativa
Crohn's disease
Pediatric Crohn's disease
Ulcerative colitis
Uveitis
pediatric uveitis
DATE:
13/04/2018
STATUS:
Authorized
Ontruzant®
Ontruzant®
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
13/04/2018
STATUS:
Authorized
Herzuma®
Herzuma®
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
16/03/2018
STATUS:
Authorized
inhixa®
inhixa®
ACTIVE PRINCIPLE:
Enoxaparin Sodium
INDICATION:
venous thrombosis
DATE:
16/03/2018
STATUS:
Authorized
ENOXAPARIN ROVI®
ENOXAPARIN ROVI®
ACTIVE PRINCIPLE:
Enoxaparin Sodium
INDICATION:
venous thrombosis
DATE:
27/02/2018
STATUS:
Authorized
CRUSIA®
CRUSIA®
ACTIVE PRINCIPLE:
Enoxaparin Sodium
INDICATION:
venous thrombosis
DATE:
20/02/2018
STATUS:
Authorized
Rixathon®
Rixathon®
ACTIVE PRINCIPLE:
rituximab
INDICATION:
Wegener's granulomatosis
microscopic polyangiitis
Rheumatoid Arthritis
Non-Hodgkin lymphoma
B-cell chronic lymphocytic leukemia
DATE:
31/07/2017
STATUS:
Authorized
Erelzi®
Erelzi®
ACTIVE PRINCIPLE:
etanercept
INDICATION:
Psoriasic arthritis
Psoriasis
Juvenile rheumatoid arthritis
Rheumatoid Arthritis
Ankylosing spondylitis
DATE:
26/07/2017
STATUS:
Authorized
Riximyo®
Riximyo®
ACTIVE PRINCIPLE:
rituximab
INDICATION:
Wegener's granulomatosis
microscopic polyangiitis
Rheumatoid Arthritis
Non-Hodgkin lymphoma
DATE:
26/07/2017
STATUS:
Authorized
Truxima®
Truxima®
ACTIVE PRINCIPLE:
Rituximab
INDICATION:
Rheumatoid Arthritis
Non-Hodgkins lymphoma
Chronic lymphocytic leukemia
Granulomatosis with polyangiitis
microscopic polyangiitis
DATE:
07/04/2017
STATUS:
Authorized
Flixabi®
Flixabi®
ACTIVE PRINCIPLE:
Infliximab
INDICATION:
Psoriasic arthritis
Rheumatoid Arthritis
Psoriasis
Ulcerative colitis
Crohn's disease
Ankylosing spondylitis
DATE:
07/07/2016
STATUS:
Authorized
Abasaglar® (formerly Abasria®)
Abasaglar® (formerly Abasria®)
ACTIVE PRINCIPLE:
Insulin glargine
INDICATION:
Diabetes Mellitus
DATE:
23/06/2016
STATUS:
Authorized
Benepali®
Benepali®
ACTIVE PRINCIPLE:
etanercept
INDICATION:
Psoriasic arthritis
Rheumatoid Arthritis
plaque psoriasis
Ankylosing spondylitis
DATE:
25/02/2016
STATUS:
Authorized
Ovaleap®
Ovaleap®
ACTIVE PRINCIPLE:
follitropin alfa
INDICATION:
Anovulation
DATE:
16/02/2015
STATUS:
Authorized
Accofil®
Accofil®
ACTIVE PRINCIPLE:
filgrastim
INDICATION:
neutropenia
DATE:
10/10/2014
STATUS:
Authorized
Bemfola®
Bemfola®
ACTIVE PRINCIPLE:
follitropin alfa
INDICATION:
Anovulation
DATE:
23/06/2014
STATUS:
Authorized
Remsima®
Remsima®
ACTIVE PRINCIPLE:
Infliximab
INDICATION:
Rheumatoid Arthritis
Crohn's disease
Ulcerative colitis
Ankylosing spondylitis
Psoriasic arthritis
Psoriasis
DATE:
23/06/2014
STATUS:
Authorized
Inflectra®
Inflectra®
ACTIVE PRINCIPLE:
Infliximab
INDICATION:
Rheumatoid Arthritis
Crohn's disease
Ulcerative colitis
Ankylosing spondylitis
Psoriasic arthritis
Psoriasis
DATE:
25/03/2014
STATUS:
Authorized
Nivestim®
Nivestim®
ACTIVE PRINCIPLE:
Filgastrim
INDICATION:
Neutropenia in the context of oncological processes
Hematopoietic stem cell transplantation
DATE:
19/10/2010
STATUS:
Authorized
Tevagastrim®
Tevagastrim®
ACTIVE PRINCIPLE:
Filgastrim
INDICATION:
Neutropenia in the context of oncological processes
Hematopoietic stem cell transplantation
DATE:
07/12/2009
STATUS:
Authorized
Zarzio®
Zarzio®
ACTIVE PRINCIPLE:
Filgastrim
INDICATION:
Neutropenia in the context of oncological processes
Hematopoietic stem cell transplantation
DATE:
31/03/2009
STATUS:
Authorized
Ratiogastrim®
Ratiogastrim®
ACTIVE PRINCIPLE:
Filgastrim
INDICATION:
Neutropenia in the context of oncological processes
Hematopoietic stem cell transplantation
DATE:
25/09/2008
STATUS:
Authorized
Retacrit®
Retacrit®
ACTIVE PRINCIPLE:
Epoetin Zeta
INDICATION:
Anemia secondary to oncological processes
end-stage renal failure
DATE:
27/02/2008
STATUS:
Authorized
Binocrit®
Binocrit®
ACTIVE PRINCIPLE:
epoetin alfa
INDICATION:
Anemia secondary to oncological processes
end-stage renal failure
DATE:
18/02/2008
STATUS:
Authorized
Omnitrope®
Omnitrope®
ACTIVE PRINCIPLE:
Somatotropin
INDICATION:
Dwarfism
Prader-Willi syndrome
Turner syndrome
DATE:
06/07/2006
STATUS:
Authorized